metformin has been researched along with Central Nervous System Neoplasms in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Central Nervous System Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This work aims to study the roles and mechanisms of metformin in glioma cells stemness and epithelial-mesenchymal transition." | 7.88 | Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity. ( Bao, Q; Chen, H; Jiang, W; Jin, P; Wei, W; Yuan, X, 2018) |
| "This work aims to study the roles and mechanisms of metformin in glioma cells stemness and epithelial-mesenchymal transition." | 3.88 | Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity. ( Bao, Q; Chen, H; Jiang, W; Jin, P; Wei, W; Yuan, X, 2018) |
| "Metformin shows preclinical anti-cancer activity through multiple pathways." | 3.30 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Metts, JL | 1 |
| Trucco, M | 1 |
| Weiser, DA | 1 |
| Thompson, P | 1 |
| Sandler, E | 1 |
| Smith, T | 1 |
| Crimella, J | 1 |
| Sansil, S | 1 |
| Thapa, R | 1 |
| Fridley, BL | 1 |
| Llosa, N | 1 |
| Badgett, T | 1 |
| Gorlick, R | 1 |
| Reed, D | 1 |
| Gill, J | 1 |
| Yuan, X | 1 |
| Wei, W | 1 |
| Bao, Q | 1 |
| Chen, H | 1 |
| Jin, P | 1 |
| Jiang, W | 1 |
1 trial available for metformin and Central Nervous System Neoplasms
| Article | Year |
|---|---|
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo | 2023 |
1 other study available for metformin and Central Nervous System Neoplasms
| Article | Year |
|---|---|
Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Shape; Cell Survival; Central Nervous S | 2018 |